Published in Drug Metab Dispos on September 24, 1982
Stereoselective propranolol metabolism in two drug induced rat hepatic microsomes. World J Gastroenterol (2000) 0.85
Metabolism of propafenone and verapamil by cryopreserved human, rat, mouse and dog hepatocytes: comparison with metabolism in vivo. Naunyn Schmiedebergs Arch Pharmacol (2004) 0.85
Propranolol oxidation by human liver microsomes--the use of cumene hydroperoxide to probe isoenzyme specificity and regio- and stereoselectivity. Br J Clin Pharmacol (1990) 0.84
Stereoselective ring oxidation of propranolol in man. Br J Clin Pharmacol (1984) 0.82
The predictable relationship between plasma levels and dose during chronic propranolol therapy. Clin Pharmacol Ther (1978) 1.51
Outcome of endoscopy and barium radiography for acute upper gastrointestinal bleeding: controlled trial in 1037 patients. Br Med J (Clin Res Ed) (1982) 1.46
Mass spectrometric analysis of integral membrane proteins at the subnanomolar level: application to recombinant photopigments. Anal Chem (2001) 1.45
Vasopressin stimulates thromboxane synthesis in the toad urinary bladder: effects of imidazole. J Pharmacol Exp Ther (1979) 1.35
Food effects on propranolol systemic and oral clearance: support for a blood flow hypothesis. Clin Pharmacol Ther (1986) 1.31
Intraductal infusion of mono-octanoin: experience in 24 patients with retained common-duct stones. Lancet (1981) 1.30
The effects of alpha adrenergic agents on human platelet aggregation. J Pharmacol Exp Ther (1979) 1.26
Transport of the flavonoid chrysin and its conjugated metabolites by the human intestinal cell line Caco-2. Biochem Pharmacol (1999) 1.25
Protective effects of thromboxane synthetase inhibitors in rats in endotoxic shock. Circ Res (1980) 1.24
GLC determination of propranolol, other beta-blocking drugs, and metabolites in biological fluids and tissues. J Pharm Sci (1974) 1.22
Disposition and metabolism of the flavonoid chrysin in normal volunteers. Br J Clin Pharmacol (2001) 1.21
Pharmacologic characterization of human and canine thromboxane A2/prostaglandin H2 receptors in platelets and blood vessels: evidence for different receptors. J Pharmacol Exp Ther (1985) 1.20
Palmitylation of a G-protein coupled receptor. Direct analysis by tandem mass spectrometry. J Biol Chem (1992) 1.19
Transport of quercetin and its glucosides across human intestinal epithelial Caco-2 cells. Biochem Pharmacol (1998) 1.18
Propranolol metabolism in man and dog: mass spectrometric identification of six new metabolites. J Pharmacol Exp Ther (1972) 1.17
Cellular uptake of dietary flavonoid quercetin 4'-beta-glucoside by sodium-dependent glucose transporter SGLT1. J Pharmacol Exp Ther (2000) 1.14
Flavonoids, potent inhibitors of the human P-form phenolsulfotransferase. Potential role in drug metabolism and chemoprevention. Drug Metab Dispos (1996) 1.11
Extensive binding of the bioflavonoid quercetin to human plasma proteins. J Pharm Pharmacol (1998) 1.10
Naphthoxylactic acid after single and long-term doses of propranolol. Clin Pharmacol Ther (1979) 1.10
Treatment of chronic gastric ulcer with carbenoxolone and gefarnate: a comparative trial. Br Med J (1973) 1.06
Transport and metabolism of the tea flavonoid (-)-epicatechin by the human intestinal cell line Caco-2. Pharm Res (2001) 1.06
Propranolol's metabolism is determined by both mephenytoin and debrisoquin hydroxylase activities. Clin Pharmacol Ther (1989) 1.05
Gall-stone dissolution and recurrence: are we being misled? Br Med J (Clin Res Ed) (1982) 1.04
Taxol transport by human intestinal epithelial Caco-2 cells. Drug Metab Dispos (1998) 1.02
Efflux of dietary flavonoid quercetin 4'-beta-glucoside across human intestinal Caco-2 cell monolayers by apical multidrug resistance-associated protein-2. J Pharmacol Exp Ther (2000) 1.01
Stereoselective binding of propranolol to human plasma, alpha 1-acid glycoprotein, and albumin. Clin Pharmacol Ther (1983) 1.01
4-Hydroxypropranolol and its glucuronide after single and long-term doses of propranolol. Clin Pharmacol Ther (1980) 1.00
Induction of UDP-glucuronosyltransferase UGT1A1 by the flavonoid chrysin in Caco-2 cells--potential role in carcinogen bioinactivation. Pharm Res (2001) 1.00
Binding of taxol to human plasma, albumin and alpha 1-acid glycoprotein. Res Commun Chem Pathol Pharmacol (1993) 1.00
Characterization of an 125I-labeled thromboxane A2/prostaglandin H2 receptor agonist. J Pharmacol Exp Ther (1989) 0.99
Methylation protects dietary flavonoids from rapid hepatic metabolism. Xenobiotica (2006) 0.99
Familial and sporadic inflammatory bowel disease: comparison of clinical features and serological markers in a genetically homogeneous population. Scand J Gastroenterol (2002) 0.98
Food-induced increase in propranolol bioavailability--relationship to protein and effects on metabolites. Clin Pharmacol Ther (1981) 0.98
Thromboxane A2 and prostaglandin endoperoxide receptors in platelets and vascular smooth muscle. Circulation (1985) 0.97
A site on transducin alpha-subunit of interaction with the polycationic region of cGMP phosphodiesterase inhibitory subunit. J Biol Chem (1993) 0.97
Extensive metabolism of the flavonoid chrysin by human Caco-2 and Hep G2 cells. Xenobiotica (1999) 0.97
Inhibition of platelet thromboxane synthesis by 7-(1-imidazolyl) heptanoic acid: dissociation from inhibition of aggregation. Thromb Res (1981) 0.96
Acetylation of spermidine and spermine by rat liver and kidney chromatin. Arch Biochem Biophys (1977) 0.95
Fate of the flavonoid quercetin in human cell lines: chemical instability and metabolism. J Pharm Pharmacol (1999) 0.95
Stereoselective sulphate conjugation of fenoterol by human phenolsulphotransferases. Xenobiotica (1997) 0.94
Stereoselective sulphate conjugation of salbutamol in humans: comparison of hepatic, intestinal and platelet activity. Br J Clin Pharmacol (1993) 0.93
Taxol metabolism and disposition in cancer patients. Drug Metab Dispos (1995) 0.93
Quercetin glucosides are completely hydrolyzed in ileostomy patients before absorption. J Nutr (2000) 0.93
Induction of UDP-glucuronosyltransferase by the flavonoids chrysin and quercetin in Caco-2 cells. Pharm Res (2000) 0.93
Exercise-induced increments in plasma levels of propranolol and noradrenaline. Br J Clin Pharmacol (1983) 0.92
Quantitative account of propranolol metabolism in urine of normal man. Drug Metab Dispos (1985) 0.92
Mass spectrometric identification of phosphorylation sites in bleached bovine rhodopsin. Biochemistry (1993) 0.92
Identification of the unusual polyamines 3,3'-diaminodipropylamine and N,N'-bis(3-aminoproply)-1,3-propanediamine in the white shrimp Penaeus setiferus. Biochem Biophys Res Commun (1977) 0.91
Quercetin and resveratrol potently reduce estrogen sulfotransferase activity in normal human mammary epithelial cells. J Steroid Biochem Mol Biol (2000) 0.90
Stereoselective clearance and distribution of intravenous propranolol. Clin Pharmacol Ther (1984) 0.90
Stimulatory as well as inhibitory effects of ethinyloestradiol on the metabolic clearances of propranolol in young women. Br J Clin Pharmacol (1996) 0.90
Quinoxaline studies. 23. Potential antimalarials. Substituted 5,8-dimethoxyquinoxalines. J Med Chem (1975) 0.90
Stereoselective sulphate conjugation of salbutamol by human lung and bronchial epithelial cells. Br J Clin Pharmacol (1996) 0.89
Mass spectrometric analysis of rhodopsin from light damaged rats. Mol Vis (2000) 0.89
S-adenosyl-L-methionine: transcellular transport and uptake by Caco-2 cells and hepatocytes. J Pharm Pharmacol (2005) 0.89
Immunochemical detection of protein adducts in mice treated with trichloroethylene. Chem Res Toxicol (1996) 0.89
Biologic determinants of propranolol disposition: results from 1308 patients in the Beta-Blocker Heart Attack Trial. Clin Pharmacol Ther (1985) 0.88
Induction of UDP-glucuronosyltransferase UGT1A1 by the flavonoid chrysin in the human hepatoma cell line hep G2. Drug Metab Dispos (2000) 0.88
Essential fatty acid deficient rats: a new model for evaluating arachidonate metabolism in shock. Adv Shock Res (1981) 0.88
Extensive and saturable accumulation of paclitaxel by the human platelet. Cancer Chemother Pharmacol (1995) 0.88
Mass spectrometric analysis of integral membrane proteins: application to complete mapping of bacteriorhodopsins and rhodopsin. Protein Sci (1998) 0.88
Hep G2 cell line as a human model for sulphate conjugation of drugs. Xenobiotica (1992) 0.87
Carbon dioxide is the major metabolite of quercetin in humans. J Nutr (2001) 0.87
Stereoselective oral bioavailability of (+/-)-propranolol in the dog. A GC-MS study using a stable isotope technique. Res Commun Chem Pathol Pharmacol (1979) 0.87
Transport of genistein-7-glucoside by human intestinal CACO-2 cells: potential role for MRP2. Res Commun Mol Pathol Pharmacol (1999) 0.87
Stereoselective increase in propranolol bioavailability during chronic dosing in the dog. J Pharmacol Exp Ther (1983) 0.86
Bioactivation of the cooked food mutagen N-hydroxy-2-amino-1-methyl-6-phenylimidazo[4,5-b]pyridine by estrogen sulfotransferase in cultured human mammary epithelial cells. Carcinogenesis (1998) 0.86
Presystemic and systemic glucuronidation of propranolol. Clin Pharmacol Ther (1979) 0.86
Platelet and vascular thromboxane A2/prostaglandin H2 receptors. Evidence for different subclasses in the rat. Biochem Pharmacol (1991) 0.86
Chemical derivatization for mass spectrometry. Methods Enzymol (1990) 0.85
A novel approach for the study of thromboxane A2 and prostaglandin H2 receptors using an 125I-labeled ligand. Biochem Pharmacol (1985) 0.85